Sanofi and GlaxoSmithKline agree a deal with EU for 300 million COVID-19 vaccine doses

The vaccine is being studied in a phase I/II study, with a planned phase III study set to begin by the end of 2020. The agreement will help Sanofi and GSK to scale-up manufacturing on the antigen and adjuvant components with the aim of producing up to one billion doses per year.

Source:

PharmaTimes